Name: 7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference
Start: 2024-06-20
End: 2024-06-21
Location: Hilton Boston Logan Airport, One Drive, Boston, MA 02128, USA

EVENT OVERVIEW

Our 7th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 20th - 21st June 2024, in Hilton Boston Logan Airport, One Drive, Boston, MA 02128, USA would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in the development of ADCs, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccine development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. With more than 20 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in the development of ADCs, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy

Updates in development of ADC’s and Bispecific Ab’s
Immune Checkpoint Inhibitors and Combinations
Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
Biomarkers and Personalized Medicine in IO
CAR-T Cell therapy, TCR Based-Cell Therapy
Tumor microenvironment and Oncolytic Viruses

Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
Find out new case studies of immune-oncology projects in development
Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
Explore the latest platforms and technologies on the market for development
Discuss the best tool for your research in immune-oncology
Share your work and achievements with your industry peers in the Poster Session

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

Monoclonal and Bispecific Antibodies
Cell Therapy
Immune Checkpoint Inhibitors

CONFERENCE AGENDA

Registration	08:15 - 08:55
Opening Remarks from the Chairperson Rakesh Dixit, CEO, Bionavigen	08:55 - 09:00
Keynote Presentation - Anchored Immunotherapy as a Better Approach for Delivery of Immuno-oncology Agents Howard Kaufman, President and CEO, Lecturer, Ankyra Therapeutics, Harvard Medical School	09:00 - 09:30
Landscape change in melanoma immunotherapy. Déjà vu or revolution? Takami Sato, Professor of Medical Oncology Research Director, Thomas Jefferson University	09:30 - 10:00
SanyouBIO One-Stop Solution for Bispecific antibody and ADC Lanye Huang, Business Development Executive/ Senior BD Manager, SanyouBio	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Enhanced Multiplex IHC Technology for Precision Oncology Aurélie Auguste, Director, Translational Data Analysis, Veracyte	11:15 - 11:45
SUPLEXA therapeutic cells, a clinically derisked cell therapy platform with unique mechanisms of action for treating solid cancers Frank Borriello, Founder and CEO, Alloplex Biotherapeutics	11:45 - 12:15
Development of methylation and mutation panel for colorectal cancer Collin Hudzik, Scientist, EpigenDx	12:15 - 12:45
Next generation translational research platforms for cell therapy in cancer Aaron Goldman, Faculty and Instructor in Medicine, Harvard Medical School	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
A Novel B7 Checkpoint Axis for Therapeutic Targeting in Cancer Leena Gandhi, Chief Medical Officer, NextPoint Therapeutics	14:15 - 14:45
Immune stimulation of myeloid cells for cancer therapy Christopher Garris, Assistant Professor of Pathology, Massachusetts General Hospital, Harvard Medical School	14:45 - 15:15
Preliminary results of a Phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors. Roger Waltzman, Chief Medical Officer, Indaptus Therapeutics	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Enhancing TCR-T Activity for Solid Tumors through Synthetic Biology and Gene Editing Allison Drain, Preclinical Development, Affini-T Therapeutics	16:30 - 17:00
Adverse Events and Safety Management: Review potential side effects of immunotherapies and best practices for managing them. Roger Waltzman, Chief Medical Officer, Indaptus Therapeutics Rakesh Dixit, CEO, Bionavigen Christopher Garris, Assistant Professor of Pathology, Massachusetts General Hospital, Harvard Medical School Takami Sato, Professor of Medical Oncology Research Director, Thomas Jefferson University Raluca Budiu-Predoiu, Director, Companion Diagnostics Strategy Lead, , Abbvie	17:00 - 17:30
Closing Remarks from the Chairperson Rakesh Dixit, CEO, Bionavigen	17:30 - 17:30

Registration	08:15 - 08:55
Opening Remarks from the Chairperson Rakesh Dixit, CEO, Bionavigen	08:55 - 09:00
Challenges and Opportunities for the development of ADCs, bispecific immunomodulatory therapies, and combination Rakesh Dixit, CEO, Bionavigen	09:00 - 09:30
ProtoNKTM Cells from Pluripotent Stem Cells: Therapeutics for All Patients Allen Feng, Founder and Chief Scientific Officer, HebeCell Corporation	09:30 - 10:00
Polyploid giant cancer cells: the senescent actuators and evil root of cancer recurrence Shriya Joshi, Scientist, small molecule drug discovery, Bristol Myers Squibb	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Intrinsic differences in tumor biology due to post translation modifications and protein-protein interactions lead to racial disparity in breast cancer Chakravarthy Garlapati, Senior Scientist, (Molecular and Cell Pharmacology), Alkermes	11:15 - 11:45
Novel antibody-enabled targeted protein stabilization (TPS2) that augments anti-tumor immune response by delivering Cbl-b inhibitor to immune cells while blocking checkpoint molecule, PD1 Joanne Lim, Associate Director, Immunology, Orum Therapeutics	11:45 - 12:15
Liquid biopsy – a step closer to realizing the power of precision oncology Raluca Budiu-Predoiu, Director, Companion Diagnostics Strategy Lead, , Abbvie	12:15 - 12:45
Panel Discussion: Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care Takami Sato, Professor of Medical Oncology Research Director, Thomas Jefferson University Aaron Goldman, Faculty and Instructor in Medicine, Harvard Medical School Shriya Joshi, Scientist, small molecule drug discovery, Bristol Myers Squibb Chakravarthy Garlapati, Senior Scientist, (Molecular and Cell Pharmacology), Alkermes	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15